Answers are grounded in this paper and cite their sources.
Systematic review uncovers multi-omics biomarkers of immune checkpoint inhibitor efficacy in NSCLC, highlighting pathways for personalized stratification.
Background and Purpose: Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet durable benefit is limited to a subset of patients. Reliable predictive biomarkers are therefore essential. We reviewed genomic, proteomic, and metabolomic studies to evaluate how multi-omics integration advances prediction of ICI efficacy in NSCLC. Methods: A systematic search of PubMed, ClinicalTrials.gov, and Google Scholar was conducted on April 11, 2024, covering studies published from 2016 through January 2025, to identify omics-based biomarkers of ICI response in NSCLC. In total, 33 genomic, 9 proteomic, and 9 metabolomic studies met inclusion criteria. Each was evaluated using a standardized evidence rubric (0– 14) assessing effect robustness, validation, cohort size, and clinical endpoint relevance. Results: Genomic predictors of poor response included EGFR and ALK/RET/ROS1 fusions, as well as KRAS co-mutations with STK11, KEAP1, or SMARCA4, all linked to immune-cold phenotypes with low tumor mutational burden (TMB) and poor T-cell infiltration. In contrast, KRAS/TP53 co-mutations, NOTCH family alterations, and BRAF V600E aligned with immune-hot signatures characterized by interferon signaling, PD-L1 upregulation, and cytotoxic T-cell infiltration. Proteomic studies consistently identified chemokines CXCL9 and CXCL10, apoptotic regulators (CASP8, FASLG), and checkpoint proteins (soluble PD-1, PD-L1, LAG-3) as predictive, while acute-phase proteins (SAA1/2, S100A8/9) correlated with resistance. Multi-analyte platforms such as PROphet demonstrated promising risk-stratification potential. Metabolomic profiling linked ICI benefit to higher baseline tryptophan, histidine, and short-chain fatty acids, while resistance was associated with increased 3-hydroxyanthranilic acid, pyruvate, and lipid metabolites indicating immunosuppressive IDO pathway activity. Conclusion: Multi-omics approaches converge on pathways governing antigenicity, interferon signaling, and immune-metabolic crosstalk. Although promising, most biomarkers require prospective validation in large, uniformly treated cohorts. Integrative strategies—particularly when combined with AI-driven analytics—hold potential to refine patient stratification and guide clinical use of ICIs in NSCLC. Plain Language Summary: Immune checkpoint inhibitors (ICIs) are a type of cancer drugs that help the body’s immune system find and attack cancer cells. They have improved treatment for non-small cell lung cancer (NSCLC), but they only work well for some patients. Doctors still struggle to predict who will benefit from these treatments. This review looks at how combining different scientific approaches—studying genes (genomics), proteins (proteomics), and small molecules in the body (metabolomics)—can help find better ways to predict treatment success. Researchers found that certain gene mutations in tumors can affect how well patients respond to ICIs. For example, some mutations are linked to poor outcomes, while others are associated with better survival. Protein studies have also discovered markers in blood and tissue that may help predict who will respond well. In addition, changes in specific body chemicals (metabolites) are linked to treatment results and can give clues about how a patient’s body is reacting to therapy. Overall, combining these “multi-omics” approaches can help doctors better understand which patients are likely to benefit from immunotherapy and could lead to more personalized and effective treatments in the future.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: